Clinical trials: Influenza Virus Infection
Healthy Volunteers, Influenza Vaccination
A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.
The objective of this study is to evaluate the safety and immunogenicity of different vaccines of hemagglutinin formulations of trivalent influenza vaccine or of a combined respiratory syncytial virus / human metapneumovirus /…
- Conditions
- Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination, Parainfluenza Vaccination
- Trial name
- NCT06850051
- Testing
- TIV-HA Vaccine formulation 1 at low dose, TIV-HA formulation 1 at high dose, TIV-HA formulation 2 at low dose
- Where
- 6 sites in Australia
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Sanofi
Asthma, Chronic Obstructive Pulmonary Disease
Effectiveness of Influenza Vaccine Reminder Systems
Influenza disease causes significant morbidity and mortality in the Unites States each year. Although influenza can cause morbidity in otherwise healthy individuals, adults with chronic lung disease have significantly increased…
- Trial name
- NCT01852656
- Testing
- Postcard and IVR Reminder Group, Postcard Only Reminder Group, IVR Only Reminder Group
- Where
- United States
- Volunteers
- 12,255 people
- Sponsor
- Kaiser Permanente
Vaccination; Infection, Maternal-Fetal Relations
Maternal Determinants of Immunity to Influenza
The overall objective of the project is to determine the impact of pregnancy on the response to influenza immunization.
- Conditions
- Vaccination; Infection, Maternal-Fetal Relations, Influenza, Immunoglobulins
- Trial name
- MADI-01 (NCT06716567)
- Testing
- Influenza vaccine
- Where
- Belgium
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Influenza, Swine-origin A/H1N1 Influenza
A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
- Trial name
- NCT00956202
- Testing
- Swine A/H1N1 influenza vaccine (split virion, inactivated), Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)
- Where
- 15 sites in Finland
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Immunosuppression
High Dose vs. Standard Influenza Vaccine in Adult SOT
The study will test whether a high dose influenza vaccination results in improved immunogenicity in adult SOT recipients as compared to standard vaccine.
- Trial name
- NCT03139565
- Testing
- Fluzone High-dose Influenza Vaccine, Standard 2016-2017 Flu vaccine
- Where
- Canada
- Volunteers
- 172 people
- Sponsor
- University Health Network, Toronto
Asthma
Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma
Trial to assess asthma exacerbation through to the end of the study; and to demonstrate that the efficacy over one season against culture-confirmed influenza-illness; and finally to assess the safety and tolerability of CAIV-T in…
- Trial name
- NCT00192257
- Testing
- CAIV-T and TIV
- Where
- 2 sites in Belgium
- Volunteers
- 2,229 people
- Sponsor
- MedImmune LLC
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the seasonal quadrivalent influenza vaccine (FLU-QIV) in adults aged 60…
- Trial name
- NCT04841577
- Testing
- RSVPreF3 OA investigational vaccine, FLU-QIV
- Where
- 14 sites in New Zealand, Panama and 1 more
- Volunteers
- 976 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Flu, Human, Influenza, Human
Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects
The aim of the study is to identify what sender/signal combinations are most persuasive in encouraging low socioeconomic males living in the U.S. to take-up seasonal flu vaccination.
- Conditions
- Flu, Human, Influenza, Human, Covid19
- Trial name
- NCT04160975
- Testing
- Video about safety and effectiveness of adult seasonal flu vaccination
- Where
- United States
- Volunteers
- 3,245 people, healthy volunteers welcome
- Sponsor
- Harvard University
Asthma in Children, Influenza Vaccine
Influenza Vaccine in Children With Asthma
The occurence of influenza can be a factor of imbalance of asthma. Asthma patients are recommended for annual influenza vaccination .
- Conditions
- Asthma in Children, Influenza Vaccine, Immunization Coverage
- Trial name
- VAGA (NCT04086628)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Central Hospital, Nancy, France
Influenza
Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults
The purpose of this study is to examine the safety and tolerability after administration of trivalent and quadrivalent cell-based virosomal influenza vaccine in healthy adults.
- Trial name
- NCT02148328
- Testing
- Trivalent virosomal influenza vaccine, Commercial vaccine 1, Quadrivalent virosomal influenza vaccine
- Where
- 4 sites in Belgium
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Seasonal Influenza
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)
The purpose of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine in healthy children aged 6-35 months.
- Trial name
- NCT03859141
- Testing
- Quadrivalent influenza vaccine, Trivalent influenza vaccine (contains B/Victoria strain), Trivalent influenza vaccine (contains B/Yamagata strain)
- Where
- 2 sites in China
- Volunteers
- 2,340 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02831751
- Testing
- 30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain)
- Where
- 15 sites in United States, Canada
- Volunteers
- 1,001 people, healthy volunteers welcome
- Sponsor
- Medicago
H7N9 Influenza
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults between the ages of 18 years and 65 years.
- Trial name
- NCT01928472
- Testing
- H7N9c low dose with adjuvant, H7N9c medium dose with adjuvant, H7N9c high dose with adjuvant
- Where
- 6 sites in United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults
This is an open label phase I study, to assess the safety of a novel influenza vaccine, MVA-NP+M1. All volunteers recruited will be healthy.
- Trial name
- NCT00942071
- Testing
- MVA-NP+M1
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Influenza
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
This is a Phase I, dose escalation study in healthy adolescents and children (6-17 years) to evaluate the safety, tolerability, and immunogenicity of a prime-boost regimen of the 2012/2013 seasonal influenza DNA vaccine (HA DNA)…
- Trial name
- NCT01609998
- Testing
- Seasonal Influenza DNA vaccine, TIV
- Where
- 5 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Influenza Vaccines
Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
Influenza pandemics are caused by viruses that possess an Hemagglutinin molecule to which most of the population lacks immunity.
- Trial name
- NCT00306995
- Testing
- SB218352_15, SB218352_8, SB218352_4
- Where
- 10 sites in Germany
- Volunteers
- 385 people
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)
The aim of the study was to assess the immunogenicity and safety of Fluzone Quadrivalent influenza vaccine Southern Hemisphere (SH) 2015 formulation in participants aged 18 to 60 years as well as in participants 61 years or…
- Trial name
- NCT03546192
- Testing
- Fluzone Quadrivalent Influenza Vaccine
- Where
- 3 sites in Philippines
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years
This is a study to assess the safety of a bioCSL split virion, inactivated Trivalent Influenza Virus vaccine containing the 2014/2015 Northern Hemisphere strains of vaccine in children aged 5 years to less than 9 years.
- Trial name
- NCT02212106
- Testing
- bioCSL Trivalent Influenza Virus Vaccine (CSL TIV), Comparator Quadrivalent Influenza Virus Vaccine
- Where
- 11 sites in United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza Immunization
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza mRNA Vaccine MRT5410 compared to an active control (QIV SD, QIV HD…
- Trial name
- NCT05624606
- Testing
- Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Quadrivalent Inactivated Influenza Standard Dose QIV-SD
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza A Virus Infection, Influenza A
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
The present clinical phase I study designed to examine the safety, reactogenicity and immunogenicity of the medicinal product - Vaccine vector against influenza A - in healthy volunteers after a single dose in the three groups…
- Conditions
- Influenza A Virus Infection, Influenza A, Influenza Epidemic, Influenza H5N1
- Trial name
- NCT03651544
- Testing
- GamFluVac
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.